News
BB Imaging takes aim at maternal mortality crisis reaching 10m patients by 2035
BB Imaging, a leading sonography services company, has announced its goal to reach 10 million patients annually in the next 10 years.
Building on its legacy of serving half a million patients nationwide, including 355,000 in Texas, the company is determined to address the urgent need for improved maternal healthcare and combat the maternal mortality crisis.
This challenge is underscored by the United States’ D-plus preterm birth grade from the March of Dimes and Texas’ even lower grade of D.
Blanca Lesmes is President, Chairperson, and Co-founder of BB Imaging.
Lesmes said: “When we started BB Imaging, we knew access to quality prenatal care was essential, but the maternal mortality rates in the United States, and especially Texas, are alarming.
“Our goal is to move the needle on this critical issue by ensuring pregnant patients, especially in underserved communities, receive timely and comprehensive prenatal ultrasounds.”
BB Imaging is committed to expanding access to maternal healthcare in areas of greatest need.
Initial expansion plans focus on Dallas, Houston, and border towns in Texas, as well as Kansas, Missouri, Tennessee, Georgia, Florida, Oklahoma, and Washington.
This strategic expansion is driven by the urgent need to improve maternal health outcomes, especially in Texas, which ranks 47th in the nation for access to prenatal care, with 22 percent of women receiving inadequate care compared to the national average of 15.7 percent.
By targeting additional markets in the future, the company will continue to expand its impact and improve maternal health outcomes across the country.
Sanjay Patel, CEO of BB Imaging, said: “We recognise the urgent need for qualified sonographers, especially in rural areas.
“The industry average to fill a sonographer role is between 36 and 42 days, but in rural settings, it can take up to 180 days.
“This delay in hiring can significantly impact patient care. BB Imaging can place highly skilled, accredited sonographers in clinics in as little as 30 days, ensuring timely access to vital diagnostic services.”
BB Imaging provides a comprehensive solution for sonography staffing, handling everything from recruitment and training to scheduling and benefits, allowing healthcare facilities to focus on what matters most: patient care.
BB Imaging employs hundreds of sonographers nationwide, with a third based in Austin. All BB Imaging sonographers are specialized, accredited professionals who meet the highest industry standards.
Looking ahead, BB Imaging is committed to partnering with healthcare providers, community organisations, and technology innovators like Telescan to expand access to prenatal care and improve maternal health outcomes.
Ben Buentipo, Chief Imaging Officer and Co-founder for BB Imaging, said: “Telescan has been a game changer.
“It allows us to bridge geographical gaps and provide timely, essential care to patients who might otherwise have limited access to specialists.
“This technology is instrumental in our mission to make quality ultrasound available to everyone.”
The company’s goal of reaching 10 million patients annually in the next 10 years underscores its dedication to transforming healthcare access for all.
Lesmes said: “We invite healthcare providers and community organizations to join us in this mission to ensure that every mother and baby has access to the quality care they deserve.”
Cancer
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






